IPP Bureau
Zydus Cadila’s Sitagliptin base tablets receive tentative approval from US FDA
By IPP Bureau - September 06, 2021
Zydus’ Sitagliptin base contains the active moiety Sitagliptin in a different form than used in the branded reference product, Januvia (Sitagliptin Phosphate)
CRAMS to drive growth for Indian pharma industry: report
By IPP Bureau - September 06, 2021
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
DGCI approves Hetero’s Tocilizumab
By IPP Bureau - September 06, 2021
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
Accutest enables NMPA approval for Qilu’s Abiraterone
By IPP Bureau - September 06, 2021
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
NF Healthcare launch latest version of its oxygen generators
By IPP Bureau - September 06, 2021
The newest entrant from the company is the MOSS 1800F with an oxygen flow rate of 180 LPM or 10.8 Nm3/hour
Alembic JV Aleor receives US FDA final approval for skin disorder gel
By IPP Bureau - September 06, 2021
Metronidazole Gel USP, 1% is indicated for the topical treatment of inflammatory lesions of rosacea
Govt revises NLEM and slashes prices of 39 drugs
By IPP Bureau - September 04, 2021
At present 18 per cent of the local pharmaceutical market is under government's price control
Reliance Strategic Business Ventures acquires Strand Life Sciences for Rs 393 crores
By IPP Bureau - September 04, 2021
The investment is part of the group's digital health initiatives, to foster affordable access to world-class technology and an innovation-led healthcare ecosystem in India
HCG acquires oncology labs and divests stake in Strand Life Sciences
By IPP Bureau - September 04, 2021
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
Reliance Life Science gets go-ahead for Phase I clinical trial for Covid-19 vaccine
By IPP Bureau - September 04, 2021
The trial will be conducted across eight sites in Maharashtra
Indian Railways to deploy HMIS across its network
By IPP Bureau - September 04, 2021
Implementation of the system to provide faster, seamless and hassle-free healthcare solutions
Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent
By IPP Bureau - September 04, 2021
In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.
DGCI green lights Biological E for Phase 2/3 trials of its Covid-19 vaccine candidate for children
By IPP Bureau - September 03, 2021
The trial will be conducted across 10 sites in India
Indigenous technology will help reduce dependence on imports: Dr Singh
By IPP Bureau - September 03, 2021
Union Minister addresses the 13th CII Global MedTech Summit on the sunrise medical devices sector in India
Omeza Collegen Matrix gets U.S. FDA approval
By IPP Bureau - September 03, 2021
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
